BMP9 Promotes Hepatocellular Carcinoma Progression By Accelerating Cell Cycle through CKS1B Lactylation
This study reveals that elevated BMP9 expression drives hepatocellular carcinoma progression by promoting CKS1B-K4 lactylation, which enhances CKS1B interaction with CDK1–3 and facilitates p27 degradation to accelerate cell cycle progression.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The Cell's Speedometer and the Sugar Rush
Imagine your body is a bustling city, and inside every building (your cells), there's a strict traffic control system. This system, called the "cell cycle," decides when a cell should stop, rest, and when it should hit the gas pedal to divide and make more cells. Usually, this traffic light is perfect: green for growth, red for rest. But in cancer, the lights get stuck on green, and the cells race out of control, building chaotic, dangerous crowds.
Scientists have long known that cancer cells are like sugar addicts. They gobble up sugar and turn it into a waste product called lactate, even when they don't need the energy. For a long time, we thought lactate was just trash. But recently, researchers discovered something wild: lactate isn't just trash; it's also a sticky note. It can attach itself to proteins inside the cell, changing how those proteins behave. This process is called "lactylation." Think of it like putting a special sticker on a worker in a factory; the sticker doesn't change who the worker is, but it tells them to work faster or slower.
Now, imagine a specific type of liver cancer called Hepatocellular Carcinoma (HCC). It's a tough enemy, and doctors are always looking for the "off switch" to stop the cancer cells from racing. A new study from researchers in China and Japan asks a big question: What if the cancer cells are using that sticky lactate note to jam the brakes and keep the gas pedal floored? They wanted to find out exactly how this sugar-sticker trick works to make liver cancer grow faster.
The Sugar Sticker That Unlocks the Engine
In this study, the team discovered a specific "sticker" that acts like a master key for liver cancer. They found that a protein called BMP9 is like a bossy manager in cancer cells. When BMP9 is present in high amounts (which happens in many liver cancer patients and is linked to a worse outlook), it tells the cell to start making more of these lactate stickers.
But here's the twist: the cancer cells don't just stick lactate on random things. The researchers found that BMP9 specifically targets a protein called CKS1B and puts a lactate sticker right on its 4th lysine spot (a tiny chemical hook on the protein). Let's call this the "CKS1B-K4 lactylation" sticker.
The Domino Effect
Once this sticker is on CKS1B, magic happens. The sticker changes the shape of CKS1B just enough to make it a better partner for other proteins called CDK1, CDK2, and CDK3. You can think of CDKs as the actual engines that drive the cell cycle forward. Normally, CKS1B helps these engines run, but with the lactate sticker, it hugs them tighter and turns the key. This makes the engines spin faster, pushing the cell through its growth phases much quicker than it should.
The Brake Failure
There's a second part to this story. Cells have a natural brake pedal called p27. This protein is a tumor suppressor; its job is to grab the CDK engines and say, "Stop! Time to rest!" But the lactate-stickered CKS1B has a dirty trick. It also grabs onto p27 and tags it for the trash can (a process called ubiquitination). Once tagged, the cell's cleanup crew destroys the p27. With the brake pedal gone, the CDK engines run wild, and the cancer cell divides non-stop.
The Boss's Playbook
The researchers didn't just stop at finding the sticker; they traced the whole chain of command. They found that BMP9 tells the cell to make more of a protein called p300. Think of p300 as the "writer" or the artist who actually applies the lactate sticker. BMP9 activates p300 by turning on a specific switch in the cell's DNA (using a molecule called pSmad1/5). Once p300 is busy, it slaps the lactate sticker onto CKS1B, starting the whole runaway train.
What They Tested and What They Didn't
The team was very careful. They didn't just guess; they tested this in liver cancer cells in a dish and in mice.
- In the lab: When they blocked BMP9 with a drug called LDN-212854, the lactate stickers disappeared, the CDK engines slowed down, and the cancer stopped growing.
- The "What-If" Test: They created a mutant version of CKS1B where the spot for the sticker was broken (so the sticker couldn't stick). In these cells, even if BMP9 was present, the cancer couldn't speed up. This proved that the sticker itself is the critical link.
- What they ruled out: They checked if the lactate was coming from a general buildup of sugar waste inside the cell. Surprisingly, the levels of lactate didn't change much when they blocked BMP9. This suggests that BMP9 isn't just making more sugar waste; it's actively reprogramming the cell to use whatever lactate is there to stick it onto CKS1B.
- Computer Simulations: To understand how the sticker changes the shape, they used computer models. These simulations suggested that the sticker doesn't change the whole protein's shape drastically, but it does tweak how CKS1B sits down next to its partners (CDKs and p27), making the connection stronger and easier.
The Bottom Line
This paper suggests that in liver cancer, BMP9 acts as a master switch that orders the cell to put a lactate sticker on CKS1B. This sticker makes CKS1B a super-helper for the growth engines (CDKs) and a super-destroyer of the brakes (p27). The result? The cancer cell zooms through its life cycle, growing into a tumor.
The researchers are hopeful because this pathway offers a new target. If doctors can block BMP9, stop the "writer" p300, or prevent that specific lactate sticker from sticking, they might be able to put the brakes back on the cancer. While this is a significant step forward in understanding the mechanics of liver cancer, the paper notes that turning this into a real medicine will take more work, especially since finding a drug that targets these protein interactions is tricky. But for now, we have a much clearer map of how the cancer cell is cheating the system.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.